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Study Population 163
Eligible patients were age ≥ 50 years with anti-VEGF-responsive nAMD in the study eye 164 diagnosed within the 9 months before screening (see Appendix S2, available at 165 www.aaojournal.org). Patients had to have received ≥ 2, but not more than 9, injections with 166 any anti-VEGF agent in the study eye. To meet anti-VEGF responsiveness criteria, the study 167 eye must either have demonstrated a documented decrease in central foveal thickness (CFT) 168 of 50 µm or stable or improved BCVA following intravitreal anti-VEGF treatment initiation. 169
Prescreening with run-in intravitreal ranibizumab treatment was available to eligible patients 170 to determine eligibility. All nAMD choroidal neovascularization (CNV) lesion subtypes were 171 
Randomization, Intervention, and Masking 179
Patients were randomly assigned 3:3:3:2 to treatment with the PDS filled with ranibizumab 10 180 mg/mL, 40 mg/mL, or 100 mg/mL formulations or to treatment with monthly intravitreal 181 ranibizumab 0.5 mg injections (Lucentis ® , Genentech, Inc., South San Francisco, CA). For 182 PDS patients, implant refills were performed on a pro re nata basis according to predefined 183 criteria. Trial duration was up to ~38 months. Randomization was performed by interactive 184 voice/web response system and stratified based on BCVA score (≤ 65 ETDRS letters vs. ≥ 66 185 ETDRS letters) and number of prior intravitreal anti-VEGF injections (≤ 3 injections vs. ≥ 4 186 injections). Visual acuity assessors were masked to both the patient study eye and patientM A N U S C R I P T
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The PDS Ladder Phase 2 Trial Ophthalmology 8 treatment. Within the PDS treatment arms, patients and all study site personnel were masked 188 to ranibizumab formulation assignment. Patients and other study site personnel were not 189 masked regarding patient assignment to either PDS treatment or monthly intravitreal 190 ranibizumab 0.5 mg injections. 191
Study Treatments and Assessments 192

Port Delivery System with Ranibizumab Implant 193
The PDS consists of a surgically implanted, refillable intraocular implant (Fig 1) designed for  194 the continuous delivery of a customized formulation of ranibizumab, as well as ancillary 195 devices for the surgical, initial fill, and in-office refill procedures. In Ladder, the PDS was 196 tested with 3 customized ranibizumab formulations (10 mg/mL, 40 mg/mL, and 100 mg/mL). 197
Port Delivery System with Ranibizumab Implant Insertion and Removal Surgery 198
Implant insertion was performed in an operating room under local anesthesia, using standard 199 sterile aseptic surgical techniques. After conjunctival peritomy in the superotemporal 200 quadrant, a stab incision at the pars plana was performed 4 mm posterior to the limbus 201 (original surgical technique); alternatively, a scleral dissection followed by ablation of the 202 exposed pars plana with 532-nm laser with additional diathermy as required was performed 203 (optimized surgical technique, implemented in the May 2016 Instructions for Use procedure 204 update). The implant, filled in the operating room with 1 of the 3 ranibizumab formulations, 205 was then inserted in the scleral wound using the PDS insertion tool, followed by careful 206 suturing of conjunctiva and Tenon's capsule to provide good coverage of the implant flange 207 (Video S1, available at www.aaojournal.org). When required by the protocol, implant removal 208 was performed using the customized PDS explant tool. The procedure was performed in an 209 operating room using standard sterile aseptic techniques and local anesthesia. 210 M A N U S C R I P T
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Port Delivery System with Ranibizumab Implant Refill Procedure 211
When required, implant refill procedures were performed in office as part of the monthly study 212 visit. Briefly, using standard aseptic techniques and local anesthesia, the PDS refill needle 213 was inserted perpendicularly through the conjunctiva and the center of the underlying implant 214 septum. For each refill, 0.1 mL of the specified ranibizumab formulation was injected into the 215 implant using a dual lumen refill needle that simultaneously withdraws the preexisting 216 ranibizumab solution remaining in the implant, ensuring total fluid exchange of old drug with 217 new drug in the reservoir (Video S2, available at www.aaojournal.org). 218
Port Delivery System with Ranibizumab Implant Refill Criteria 219
All PDS patients were assessed at each monthly visit and implant refills were performed if 220 any of the following occurred due to nAMD disease activity: 1) increase in CFT ≥ 75 µm on 221 spectral domain optical coherence tomography (SD-OCT) at the current visit compared with 222 the average CFT over the last 2 available measurements, 2) increase in CFT of ≥ 100 µm 223 from the lowest CFT measurement on study, 3) decrease of ≥ 5 letters in BCVA at the current 224 visit compared with the average BCVA over the last 2 available measurements, 4) decrease 225 of ≥ 10 letters from best recorded BCVA on study, or 5) presence of new macular 226 hemorrhage. Best-corrected visual acuity and CFT criteria were slightly modified during the 227 trial; see Appendix S3, available at www.aaojournal.org, for a full description of modifications. 228
Port Delivery System with Ranibizumab Rescue Criteria and Treatment 229
Open-label intravitreal ranibizumab 0.5 mg injections were available to all PDS patients 1-2 230 months after vitreous hemorrhage associated with BCVA loss, if neither assessment of the 231 macula nor SD-OCT could be performed, if lack of clinical efficacy criteria were met, or in 232 case of progressive worsening of BCVA and/or CFT over 2 consecutive visits due to nAMD 233 disease activity that did not hit thresholds to trigger a refill (discussion with medical monitor 234 necessary). Lack of clinical efficacy was defined as: 1) BCVA loss of ≥ 15 letters from bestM A N U S C R I P T
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The PDS Ladder Phase 2 Trial Ophthalmology 10 recorded BCVA following 2 consecutive implant refills occurring 1 month apart due to nAMD 236 disease activity unless there was ≥ 5-letter increase in BCVA that would trigger an implant 237 refill, or 2) an increase in CFT of ≥ 150 µm from lowest recorded CFT measurement following 238 2 consecutive implant refills occurring 1 month apart unless there was a decrease in CFT ≥ 239 75 µm from last refill that would trigger implant refill (Appendix S3). 240
When the trial started, implant removal was mandated if lack of clinical efficacy criteria 241 were met. Subsequent internal assessment of 8 explanted implants determined that lack of 242 clinical efficacy was not associated with inadequate implant performance or implant clogging. 243
The trial protocol was then amended so patients meeting lack of clinical efficacy criteria could 244 keep the implant in the eye, receive a rescue open-label intravitreal ranibizumab 0.5 mg 245 injection, and undergo a mandatory implant refill with the 100 mg/mL formulation at the next 246 monthly visit. At all subsequent visits, patients were assessed for implant refill criteria, and if 247 criteria were met, implant refill was performed with the ranibizumab 100 mg/mL formulation 248 (Appendix S3). 249
Monthly Intravitreal Ranibizumab 0.5 mg Injections 250
In the control arm, patients received intravitreal ranibizumab 0.5 mg injections (50 µL of the 251 10 mg/mL US Food and Drug Administration-approved formulation) at day 1 and then at 252 each monthly visit through trial completion. 253
Assessments 254
Standard safety and ocular assessments, including BCVA and CFT, were performed at each 255 monthly visit. In the PDS treatment arms, additional safety and functional outcomes were 256 assessed at days 2, 7, and 14 to monitor the implant insertion procedure; additional safety 257 assessments were also performed 7 days after each implant refill. 258 M A N U S C R I P T
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Outcomes 259
The prespecified primary efficacy endpoint was the time to first implant refill assessed when 260 the last enrolled patient completed the month 9 visit. Secondary efficacy outcomes included 261 change in visual function and changes in CFT, as assessed by the central reading center. 262
Central foveal thickness measurements were conducted using 2 methods. The prespecified 263 measurement was performed from the inner limiting membrane to Bruch's membrane. The 264 second, additional measurement, was performed from the inner limiting membrane to the 265 retinal pigment epithelium, excluding pigment epithelial detachment (PED) height. Explanted 266 implants were visually inspected to assess implant integrity and in vitro drug release 267 evaluations were performed to assess implant functionality. In addition, samples were 268 collected for serum pharmacokinetics and antidrug antibody (ADA) assessment. Safety 269 outcomes were assessed through a summary of ocular and nonocular adverse events (AEs) 270 and incidence of ADA. Prespecified PDS-associated AEs were also assessed. 271
Data Analysis and Statistical Methods 272
An estimated trial sample size of 220 randomized patients was determined to be adequate to 273 meet the primary objective of evaluating the relative efficacy of the ranibizumab 10 mg/mL, 274 40 mg/mL, and 100 mg/mL formulations as assessed by time to first implant refill. A sample 275 size of ~60 patients in each PDS treatment arm provided 80% power to detect a hazard ratio 276 (HR) of 0.66 in time to first implant refill between the PDS 10 mg/mL and PDS 100 mg/mL 277 treatment arms using a log-rank test at a 1-sided significance level of 15% assuming 85 278 events occurred at the time of primary analysis. 279
Efficacy outcomes were evaluated in the modified intent-to-treat population comprised 280 of patients who were randomized to a study treatment arm and received ≥ 1 study treatment. 281
The safety-evaluable population comprised all patients who received ≥ 1 dose of study drug 282 according to the assigned treatment. Time to first implant refill analysis was conducted usingM A N U S C R I P T
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The PDS Ladder Phase 2 Trial Ophthalmology observed data. The censoring date was defined as the date of a patient's last visit before the 284 cutoff date or the date when the patient discontinued from the study, whichever occurred first. 285
Time to first implant refill was also censored for the following patients: 1) at the time of an 286 intravitreal anti-VEGF injection in study eye if administered before the first required refill; 2) at 287 the time the refill criteria could not be assessed, defined as when efficacy, and pharmacokinetics of the PDS filled with ranibizumab 100 mg/mL in patients with 315 nAMD who required ongoing oral antithrombotic therapy was conducted as part of the Ladder 316 trial. The substudy was initiated at selected sites (Appendix S1) after Ladder enrollment was 317 complete and enrolled a separate trial population of 11 patients who were on oral 318
antithrombotic therapy for a preexisting medical condition. The primary endpoint of the 319 substudy was the rate of vitreous hemorrhage secondary to choroidal bleeding that did not 320 spontaneously resolve by the month 1 visit after implant insertion surgery. Oral antithrombotic 321 substudy patients were evaluated separately and were not included in any of the main Ladder 322 analyses. 323
Results
324
Patient Disposition 325
A total of 232 patients with nAMD were randomized 3:3:3:2 to 1 of 4 treatment arms: 1) PDS 326 ranibizumab 10 mg/mL, 2) PDS ranibizumab 40 mg/mL, 3) PDS ranibizumab 100 mg/mL, or 327 4) monthly intravitreal ranibizumab 0.5 mg injections. The first patient was enrolled on 328 September 29, 2015, and the last patient was enrolled on September 5, 2017. The data from 329 7 patients were unusable due to a breach of Good Clinical Practice at 1 study site and 330 another 5 randomized patients were never treated, resulting in a modified intent-to-treat 331 population of 220 patients with 58, 62, 59, and 41 patients in the PDS 10 mg/mL, 40 mg/mL,M A N U S C R I P T
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The PDS Ladder Phase 2 Trial Ophthalmology 14 100 mg/mL, and monthly intravitreal ranibizumab 0.5 mg injection arms, respectively ( Fig S1,  333 available at www.aaojournal.org). For the primary analysis, the modified intent-to-treat and 334 safety populations were identical (N = 220). At the time of the primary analysis, the 335 percentages of patients that withdrew from the study or discontinued treatment in the study 336 eye were comparable across treatment arms (Fig S1) . Of the 220 patients in the modified 337 intent-to-treat population, 11 (5.0%) discontinued the study and 18 (8.2%) discontinued 338 treatment in the study eye. 339
Demographics and Baseline Characteristics of the Study Population 340
Baseline demographic and ocular characteristics are summarized in Table 1 . Overall patient 341 demographics were well balanced across treatment arms. Ocular characteristics were 342 generally well balanced across arms, with a slight imbalance in CFT with increased baseline 343 values in 2 of the PDS arms. The imbalance was minimized when PED height was excluded. 344
Also of note was the generally good baseline vision across arms, with two-thirds of all 345 patients having 20/40 or better vision at baseline. In the overall population, the mean number 346 of anti-VEGF injections before baseline was 2.9. 347
Primary Efficacy Outcome 348
The prespecified primary outcome measure was the time to first implant refill assessed when 349 the last patient enrolled completed the month 9 visit, at which point the mean (range) time on 350 study was 16.8 (9.8-33.0) months for all PDS patients. A Kaplan-Meier survival analysis was 351 used to compare rates at which first implant refills occurred in each PDS treatment arm (Fig  352   2A ). The median time to first implant refill was 8.7, 13.0, and 15.0 months in the PDS 10 353 mg/mL, 40 mg/mL, and 100 mg/mL arms, respectively. The percentage of patients who did 354 not require an implant refill for ≥ 6 months was 63.5%, 71.3%, and 79.8% in the PDS 10 355 mg/mL, 40 mg/mL, and 100 mg/mL arms, respectively (Fig 2B) . In a stratified analysis that 356 adjusted for baseline BCVA and number of prior anti-VEGF injections, the median time to firstM A N U S C R I P T
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Secondary Efficacy Outcomes 366
Vision Outcomes 367
Because patients were previously treated and anti-VEGF responsive with good baseline 368 BCVA, the treatment arms were assessed for their ability to maintain baseline vision. A dose 369 response was observed across the PDS arms. At month 9, the adjusted mean BCVA change 370 from baseline in the PDS 10 mg/mL, 40 mg/mL, and 100 mg/mL arms was -3.2, -0.5, and 371 +5.0 ETDRS letters, respectively. At month 9, the mean adjusted BCVA change from 372 baseline was +3.9 ETDRS letters in the monthly intravitreal ranibizumab 0.5 mg injection arm 373 (Fig 3) . At month 9, there was a +1.1 (95% CI, -2.4, +4.7) ETDRS letter difference between 374 the PDS 100 mg/mL and monthly intravitreal ranibizumab 0.5 mg injection arms. Neither a 375 noninferiority (NI) test nor a NI margin were prespecified in Ladder. In a post hoc analysis 376 assuming a 4.5 ETDRS letter NI margin, the NI test was met between the PDS 100 mg/mL 377 and monthly intravitreal ranibizumab 0.5 mg injection treatment arms at month 9 (lower 378 bound of the 95% CI in the difference calculation was larger than 4.5 ETDRS letters). These 379 results indicate that vision outcomes in the PDS 100 mg/mL arm were comparable with that 380 of the monthly intravitreal ranibizumab 0.5 mg injection treatment arm. 381 Figure 3 and a dose response was also observed across the PDS 383 arms for the percentage of patients with a mean BCVA improvement from baseline of ≥ 5 or ≥ 384 10 ETDRS letters at month 9 (Table S1 , available at www.aaojournal.org). In the PDS arms, 385 there was a temporary and reversible postinsertion surgery drop in vision that was expected 386 after vitreoretinal surgery. In the overall population, vision generally returned to baseline by 387 month 2; in PDS patients who were implanted after the May 2016 procedure update, the drop 388 in BCVA from baseline was reduced in magnitude and vision generally returned to baseline 389 by month 1 (Fig S3, available at www.aaojournal.org). 390
Anatomic Outcomes 391
Similar to vision outcomes, as Ladder patients were previously treated with and responsive to 392 anti-VEGF therapy, patients were assessed for their ability to maintain baseline CFT (Fig 4) . 393
As with baseline values, variability in CFT change from baseline across arms was generally 394 reduced when subfoveal PED height was excluded. At month 9, adjusted mean CFT change 395 from baseline excluding PED height was +54.4 µm, -0.5 µm, -1.7 µm, and -6.3 µm in the 396 PDS 10 mg/mL, 40 mg/mL, and 100 mg/mL and monthly intravitreal ranibizumab 0.5 mg 397 injection treatment arms, respectively. At month 9, adjusted mean CFT change from baseline 398 including PED height was +57.4 µm, 22.2 µm, 11.1 µm, and -29.3 µm in the PDS 10 mg/mL, 399 40 mg/mL, and 100 mg/mL and monthly intravitreal ranibizumab 0.5 mg injection treatment 400 arms, respectively (Fig 4) . Observed data (Fig S4, available at www.aaojournal.org) were 401 similar to the MMRM analysis shown in Figure 4 . 402
Implant Functionality and Drug Exposure 403
In the early part of the trial, patients who experienced progressive nAMD disease worsening 404 that met lack of clinical efficacy criteria underwent surgical removal of the PDS implant to 405 evaluate implant functionality. At the time of the primary analysis, 12 PDS implants had beenM A N U S C R I P T
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The time of explant ranged from day 8 to day 500 following implant insertion, with a median 408 time of explanation of 274 days. Measurable levels of ranibizumab were present in serum at 409 the time of implant removal, suggesting that drug was still being released from the reservoir 410 into the eye and exiting the eye into the systemic circulation. In vitro testing of 8 explanted 411 implants confirmed that all implants had appropriate release of ranibizumab with no evidence 412 of clogging. Because implant functionality was not a cause for lack of clinical efficacy, the 413 protocol was amended to allow PDS patients who met the lack of clinical efficacy criteria to 414 keep the implant in the eye with a modified treatment protocol (see Methods and Appendix 415 S3). 416
At the time of the primary analysis, the mean time on study was 16.8 months for 417 patients in the PDS treatment arms and 16.4 months for patients in the monthly intravitreal 418 ranibizumab 0.5 mg injection arm (Table 3 ). The mean total number of ranibizumab 419 treatments was 3.7, 2.6, and 2.4 in the PDS 10 mg/mL, 40 mg/mL, and 100 mg/mL treatment 420 arms, respectively. In contrast, the total number of ranibizumab treatments was 16.8 in 421 patients in the monthly intravitreal ranibizumab 0.5 mg injection treatment arm. In total, 422 22.4%, 4.8%, and 1.7% of patients in the PDS 10 mg/mL, 40 mg/mL, and 100 mg/mL 423 treatment arms, respectively, met lack of clinical efficacy criteria. In the PDS 10 mg/mL and 424 40 mg/mL treatment arms, the majority of patients (11/16) who met lack of clinical efficacy 425 criteria kept the PDS implant and were managed with rescue intravitreal ranibizumab 426 treatment and implant refills with the ranibizumab 100 mg/mL formulation. 427
Safety 428
As expected given the surgical nature of the study, more ocular AEs were observed in the 429 PDS arms than in the monthly intravitreal ranibizumab 0.5 mg injection arm, particularly 430 during the perioperative period (Table S2, In general, the systemic safety profile of PDS treatment was comparable with monthly 453 intravitreal ranibizumab 0.5 mg injection treatment (Table S3, available at  454 www.aaojournal.org). There was, however, a higher rate of a few System Organ Class events 455 in the PDS treatment arms compared with the monthly intravitreal ranibizumab 0.5 mg arm.
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Additional Assessments 468
In terms of pharmacokinetics, in vitro studies have shown that ranibizumab release from the 469 PDS is a function of concentration in the reservoir and decays exponentially over time, 470 following Fick's law. 21 In the current study, active ranibizumab was measurable (with a lower 471 limit of quantification of 15 pg/mL) 22 in serum for ≥ 15 months after insertion of the PDS 472 implant filled with ranibizumab 100 mg/mL, as would be expected based on the in vitro 473 studies. Antidrug antibody development was also assessed (Table S5, available at  474 www.aaojournal.org). Because all Ladder patients were previously treated with ranibizumab, 475 ADA status at time of study entry may reflect response to previous ranibizumab treatment in 476 the study or fellow eye, rather than treatment-naïve prevalence. Overall, at the time of the 477 primary analysis, the percentages of patients in each arm who were ADA positive at time of 478 study entry (0-10.5%) or developed treatment-emergent ADAs during the course of the study 479 (3.5-13.6%) were within the range observed in previous clinical trials with ranibizumab 480 administered via intravitreal injection.
3,7,23
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Oral Antithrombotic Agent Substudy 482
Patients on an oral antithrombotic agent were prohibited from enrolling in the main Ladder 483 trial, resulting in the exclusion of a large number of otherwise eligible patients. Once it was 484 determined that laser ablation of the pars plana before incision markedly reduced the 485 incidence and severity of vitreous hemorrhage after PDS implant insertion, a substudy was 486 initiated in a limited number of study sites to determine the safety of the optimized implant 487 insertion procedure in patients on oral anticoagulants. Eleven patients with nAMD on oral 488 antithrombotic therapy were recruited and received the PDS implant with the ranibizumab 489 100 mg/mL formulation. Interruption of the antithrombotic agent before PDS implant insertion 490 was left to the discretion of the investigator after consultation with the prescribing physician to 491 assess the risk based on the needs of each patient and the antithrombotic agent in question. 
Discussion
501
The phase 2 Ladder trial met its primary objective and successfully assessed the relative 502 efficacy of PDS treatment with ranibizumab 10 mg/mL, 40 mg/mL, and 100 mg/mL 503 formulations. For primary and secondary vision endpoints, a dose response was observed 504 across the PDS treatment arms, with patients in the PDS 100 mg/mL treatment arm 505 M A N U S C R I P T
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Results for the PDS 100 mg/mL were the most promising, with a median time to first implant 508 refill of 15.0 months and 79.8% of patients who went ≥ 6 months without meeting implant refill 509 criteria. PDS treatment also successfully reduced the overall treatment burden for patients, 510
with PDS patients receiving ~80% fewer ranibizumab treatments than patients in the monthly 511 intravitreal ranibizumab 0.5 mg injection treatment arm at the time of the primary analysis. 512
Importantly, vision and anatomic outcomes at month 9 were comparable between patients in 513 the PDS 100 mg/mL arm and patients in the monthly intravitreal ranibizumab 0.5 mg injection 514 treatment arm, indicating that clinical efficacy need not be sacrificed to reduce treatment 515 burden. Taken together, these results suggest that the PDS is a good candidate to change 516 the treatment paradigm in nAMD and respond to the current unmet need to reduce treatment 517 burden while maintaining or improving patient outcomes. 518
While the optimized PDS implant insertion surgery and in-office refill procedure were 519 generally well tolerated, the Ladder trial also provided a number of valuable technical insights 520 into the best surgical methods for PDS implant insertion. The high rate of vitreous 521 hemorrhage following PDS implant insertion early in the trial (11/22 patients [50%]) led to 522 enrollment being temporarily paused. This allowed for a preclinical surgical study to be 523 conducted as part of a comprehensive analysis to determine the root cause of the vitreous 524 hemorrhage. Based on the study results that identified the pars plana at the incision site as 525 the main source of bleeding, 24 an optimized surgical procedure that included laser ablation of 526 the pars plana at the incision site was implemented in the study when enrollment restarted. 527
Following the introduction of the optimized surgical procedure, the incidence of postoperative 528 vitreous hemorrhage decreased to less than 5% (7/157 patients).
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The reduction in the incidence of vitreous hemorrhage after optimization of the implant 530 insertion procedure raised the question of whether patients on an oral antithrombotic therapy 531 could safely undergo PDS implant insertion. This is an important question, because ~25% of 532 patients with nAMD are on an oral antithrombotic therapy.
21 A small substudy of 11 patients 533 with nAMD receiving concurrent treatment with different antithrombotic agents helped to 534 address this question. While the substudy was not powered to assess meaningful differences 535 between patients who did and did not interrupt oral antithrombotic treatment, it did generate 536 useful information regarding whether laser ablation of the pars plana was sufficient to mitigate 537 the risk of vitreous hemorrhage in this patient population, which has a higher risk of bleeding. 538
As none of the patients experienced vitreous hemorrhage after PDS implant insertion, the 539 results suggest there is a low risk of vitreous hemorrhage for patients with nAMD on 540 anticoagulants who undergo the optimized PDS implant insertion procedure. 541
Additional clinically relevant AEs related to the PDS implant insertion procedure, 542 including endophthalmitis, rhegmatogenous retinal detachment, retinal tears, and conjunctival 543 erosion or retraction were reported in PDS patients. These events were managed accordingly 544 and did not result in severe vision loss. Overall, postsurgical AEs in PDS-treated patients 545
were consistent with what would be expected for similar surgical procedures. Videos of each 546 implant insertion procedure were analyzed to identify areas for improvement of the surgical 547 procedure to minimize the risk of procedure-related AEs. Rigorous surgical training has been 548 instituted with the aim to help further mitigate the risk of AEs as the PDS continues to be 549 developed and studied. 550
As an indwelling nonbiodegradable implant, the PDS is one of a number of strategies 551 being tested in clinical trials aimed at achieving sustained intravitreal suppression of VEGF. The heterogeneous response of patients with nAMD to bolus intravitreal injections is 567 one of the more challenging aspects of nAMD management. While the idea of individualizing 568 treatment by identifying the optimal interval between injections to prevent recurrences is 569 appealing, disease activity can vary over time in the same patient, allowing occasional 570 disease reactivation and associated vision loss. With 79.8% of patients in the PDS 100 571 mg/mL arm going ≥ 6 months before requiring an implant refill, the data suggest that PDS 572 treatment may introduce disease control predictability to the management of what has to date 573 been an unpredictable disease. Furthermore, pharmacokinetic analysis indicates that the 574 patients who met implant refill criteria before month 6 were still having ranibizumab released 575 into the eye. Taken together, these results indicate that with the PDS, it may be feasible to 576 use a fixed multimonth refill schedule to reduce treatment burden without sacrificing efficacy 577 in patients with nAMD. 578 M A N U S C R I P T
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A limitation of this study is the unavoidable variability that occurs in any clinical trial 579 that has a surgical component. A number of steps were taken to reduce, manage, and learn 580 from this variability, including surgical training aimed to standardize the surgical procedure 581 across investigators, support from well-trained study team members during PDS implant 582 insertion and refill procedures, and video recording for documentation, review, and study. 583
This provided important learnings that contributed to the optimization of the implant insertion 584 and refill procedures and shaped the investigator training plan for future studies. While the 585 procedural and protocol amendments throughout the course of the study would be 586 considered a weakness of a pivotal study, they allowed this phase 2 trial to efficiently 587 evaluate a novel method for continuous delivery with a surgical component for the first time 588
on a large scale. Initial learnings in Ladder led to the optimization of study methods and 589 procedures that will help to enhance the safety and efficacy for future trials. Another limitation 590 is that Ladder enrolled patients who were responsive to anti-VEGF treatment and were 591 diagnosed with nAMD in the study eye within 9 months from the screening visit; therefore, the 592 results may not be generalizable to patients with a longstanding nAMD diagnosis who have 593 been receiving anti-VEGF treatment for years. Further studies will be needed to assess the 594 usefulness of the PDS in different nAMD populations. 595
In conclusion, the phase 2 Ladder trial of the PDS evaluated the efficacy and safety of 596 In the PDS 10 mg/mL, 40 mg/mL, and 100 mg/mL arms, 2 of 13, 0 of 3, and 2 of 6 patients, 7 respectively, received rescue treatment because implant refill criteria could not be assessed 8 due to vitreous hemorrhage. 9 M A N U S C R I P T
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Conjunctival filtering bleb leak 0 0 1 (1.6%) 0 0 0 1 (0.6%) 0 2 M A N U S C R I P T
The PDS Ladder Phase 2 Trial Ophthalmology 2 Observed data, safety-evaluable population. Month 1 visit included data up to 37 days. At the time of the primary analysis, no 3 Port Delivery System with ranibizumab (PDS) patients reported any the remaining protocol-specified PDS-associated adverse 4 events: vitreous hemorrhage associated with a > 30 Early Treatment Diabetic Retinopathy (ETDRS) letter decrease of best-5 corrected visual acuity (BCVA) compared with the last assessment of BCVA before the onset of vitreous hemorrhage lasting > 6 1 month, > 30 ETDRS letters BCVA loss from previous scheduled visit, scleral damage, and interference of the implant in the 7 visual field. 8 *Proportion of phakic patients at baseline was similar across treatment arms; in the monthly intravitreal ranibizumab 0.5 mg 9 injection arm, the incidence of cataract was 3 (7.3%) for onset > 1 month and 0 for onset ≤ 1 month. 10
